ReviewMedComm2026
Epigenetic Regulation in Cardiovascular Diseases: Mechanisms and Therapeutic Targets.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nutritional Prevention of Oxidative Stress-Induced Cardiotoxicity in Pediatric Cardio-Oncology: Molecular Mechanisms and Translational Perspectives-A Narrative Review.International journal of molecular sciences · 2026Review
- Association between sarcopenia and the risk of diabetic cardiomyopathy in patients with type 2 diabetes mellitus: a single-center retrospective cohort study.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) arise as the product of multiple factors, including genetic predisposition and environmental exposure, but the molecular and cellular interplays underlying such a pathogenetic process leading to sustained pathological conditions remain largely unknown. A growing body of evidence indicates that epigenetic mechanisms, including DNA methylation, histone modifications, chromatin remodeling, noncoding RNAs, and RNA modifications, are important for cardiovascular development, adaptation, and disease. However, findings from these studies are fragmented across different genomic contexts or disease-focused scenarios, lacking systematic integration for a global view connecting epigenetic dynamics to cardiovascular phenotypes and their clinical implications. An overall picture of epigenetic modulation in CVDs is therefore provided. Common epigenetic mechanisms are described in a cell type and disease stage-specific context, and the roles of environmental and lifestyle factors in remodeling the cardiovascular epigenome are illustrated. Novel epigenetic biomarkers and therapeutic interventions are also assessed. Emphasis is placed on epigenomic plasticity, enhancer focused control, and network-level reprogramming as key concepts that drive disease remodeling. By unifying mechanistic understanding with translational evidence, this review frames CVD as a disorder of stabilized regulatory states and defines avenues for precision epigenomic manipulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.